A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia

References

• Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123–3127. doi: 10.1002/cncr.26679
   PubMed Web of Science ®Google Scholar
• Bower H, Björkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–2857. doi: 10.1200/jco.2015.66.2866
   PubMed Web of Science ®Google Scholar
• Atallah EL, Sadek I, Maegawa R, et al. Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates. Leuk Lymphoma. 2021 Jul;62(7):1730–1739. doi: 10.1080/10428194.2021.1885656 Epub 2021 Mar 1. PMID: 33648418.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al. European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10;27(35):6041–51. doi: 10.1200/JCO.2009.25.0779 Epub 2009 Nov 2. PMID: 19884523; PMCID: PMC4979100.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Ali R, Alnıgenis E, et al. Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. Expert Rev Hematol. 2022 Feb;15(2):97–106.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966–984. doi: 10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Saydam G, Ali R, Demir AM, et al. The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Int J Hematol Oncol. 2022 May 24;11(1):IJH38.
   PubMedGoogle Scholar
• Shah NP, Bhatia R, Altman JK, et al. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 Feb;22(1):43–69. doi: 10.6004/jnccn.2024.0007. PMID: 38394770.
   PubMedGoogle Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24);2260–70. doi: 10.1056/NEJMoa1002315 Epub 2010 Jun 5. PMID: 20525995.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24);2251–9. doi: 10.1056/NEJMoa0912614 Epub 2010 Jun 5. PMID: 20525993.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018 Jan 20;36(3):231–237. doi: 10.1200/JCO.2017.74.7162 Epub 2017 Nov 1. PMID: 29091516; PMCID PMC5966023.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al., International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28;346(9):645–652. doi: 10.1056/NEJMoa011573 Erratum in: N Engl J Med 2002 Jun 13;346(24):1923. PMID: 11870241.
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13;348(11):994–1004. doi: 10.1056/NEJMoa022457
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017 Mar 9;376(10):917–927. doi: 10.1056/NEJMoa1609324
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001 Apr 5;344(14):1031–7. doi: 10.1056/NEJM200104053441401
   PubMed Web of Science ®Google Scholar
• Liu Y, Fang B, Jiang J, et al. Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: an updated meta-analysis. J Cancer Res Ther. 2016 Oct;12(Supplement):23–26. doi: 10.4103/0973-1482.191623 PMID: 27721246.
   PubMedGoogle Scholar
• Sahin F, Saydam G, Cömert M, et al. Turkish chronic myeloid leukemia study: retrospective sectional analysis of CML patients. Turk J Haematol. 2013 Dec;30(4):351–8. doi: 10.4274/tjh.2013.0151 Epub 2013 Dec 5. PMID: 24385824; PMCID: PMC3874976.
   PubMed Web of Science ®Google Scholar
• Pou M, Saval N, Vera M, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma. 2003 Jul;44(7):1239–41. doi: 10.1080/1042819031000079140 PMID: 12916879.
   PubMed Web of Science ®Google Scholar
• Sakurai M, Kikuchi T, Karigane D, et al. Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. Int J Hematol. 2019 Mar;109(3):292–298. doi: 10.1007/s12185-019-02596-z Epub 2019 Jan 24. PMID: 30680668.
   PubMed Web of Science ®Google Scholar
• Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015 May;29(5):1123–32. doi: 10.1038/leu.2015.36 Epub 2015 Feb 13. PMID: 25676422.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O’Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 Jan 20;28(3):398–404. doi: 10.1200/JCO.2009.25.4920 Epub 2009 Dec 14. PMID: 20008620; PMCID: PMC2815702.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016 Jul 10;34(20):2333–40. doi: 10.1200/JCO.2015.64.8899 Epub 2016 May 23. PMID: 27217448; PMCID: PMC5118045.
   PubMed Web of Science ®Google Scholar
• Naqvi K, Jabbour E, Skinner J, et al. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 Jul 1;124(13):2740–2747. doi: 10.1002/cncr.31357. Epub 2018 May 3. PMID: 29723397; PMCID: PMC6388399.
   PubMed Web of Science ®Google Scholar
• Naqvi K, Jabbour E, Skinner J, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 Jan 1;126(1):67–75. doi: 10.1002/cncr.32504 Epub 2019 Sep 25. PMID: 31553487; PMCID: PMC8529949.
   PubMed Web of Science ®Google Scholar
• Murai K, Ureshino H, Kumagai T, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021 Dec;8(12):e902–e911. doi: 10.1016/S2352-3026(21)00333-1 PMID: 34826413.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jimenez CA, Mauro MJ, et al. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk. Clin Lymphoma Myeloma Leukemia. 2017 Feb;17(2):78–82. doi: 10.1016/j.clml.2016.09.012 Epub 2016 Sep 17. PMID: 28082112.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Laneuville P, Rousselot P, et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 2019 Jan;104(1):93–101. doi: 10.3324/haematol.2018.188987 Epub 2018 Aug 9. PMID: 30093398; PMCID: PMC6312029.
   PubMed Web of Science ®Google Scholar
• La Rosée P, Martiat P, Leitner A, et al. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol. 2013 Oct;92(10):1345–1350. doi: 10.1007/s00277-013-1769-2 Epub 2013 Apr 28. PMID: 23625298.
   PubMed Web of Science ®Google Scholar
• Iurlo A, Galimberti S, Abruzzese E, et al. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Ann Hematol. 2018 Jan;97(1):95–100. doi: 10.1007/s00277-017-3144-1 Epub 2017 Oct 2. PMID: 28971265.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Eyice D, Kurt EA, et al. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leuk Res. 2014 Jul;38(7):781–7. doi: 10.1016/j.leukres.2014.04.004 Epub 2014 Apr 18. PMID: 24832371.
   PubMed Web of Science ®Google Scholar
• Weatherald J, Chaumais MC, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J. 2017 Jul 27;50(1):1700217. doi: 10.1183/13993003.00217-2017 PMID: 28751413.
   PubMed Web of Science ®Google Scholar
• Özgür Yurttaş N, Eşkazan AE. Dasatinib-induced pulmonary arterial hypertension. Brit J Clinical Pharma. 2018 May;84(5):835–845. doi: 10.1111/bcp.13508 Epub 2018 Mar 6. PMID: 29334406; PMCID: PMC5903230.
   PubMed Web of Science ®Google Scholar
• El-Dabh A, Acharya D. Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. Pulm Circ. 2019 Jul 5;9(3):2045894019865704. doi: 10.1177/2045894019865704 Epub ahead of print. PMID: 31274047; PMCID: PMC6664660.
   Web of Science ®Google Scholar
• Rosti G, Palandri F, Castagnetti F, et al. GIMEMA CML Working Party. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009 Dec 3;114(24):4933–4938. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12. PMID: 19822896.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 May;30(5):1044–54. doi: 10.1038/leu.2016.5 Epub 2016 Feb 3. PMID: 26837842; PMCID: PMC4858585.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 Feb;35(2):440–453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7. Erratum in: Leukemia. 2021 Jul;35(7):2142–2143. PMID: 33414482; PMCID: PMC7862065.
   PubMed Web of Science ®Google Scholar
• Singer JB, Shou Y, Giles F, et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia. 2007 Nov;21(11):2311–5. doi: 10.1038/sj.leu.2404827 Epub 2007 Jul 5. PMID: 17611564.
   PubMed Web of Science ®Google Scholar
• Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood. 2008 Feb 15;111(4):2329–38. doi: 10.1182/blood-2007-05-092056 Epub 2007 Dec 4. PMID: 18056843; PMCID: PMC2234062.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27;118(17):4567–4576. doi: 10.1182/blood-2011-05-355594 Epub 2011 Aug 24. Erratum in: Blood. 2013 Oct 3;122(14):2524. PMID: 21865346; PMCID: PMC4916618.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr 12;119(15):3403–12. doi: 10.1182/blood-2011-11-390120 Epub 2012 Feb 27. PMID: 22371878; PMCID: PMC4916559.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 1;30(28):3486–92. doi: 10.1200/JCO.2011.38.7522 Epub 2012 Sep 4. PMID: 22949154; PMCID: PMC4979199.
   PubMed Web of Science ®Google Scholar
• Gambacorti Passerini C, Lipton J, Hochhaus A, et al. Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with philadelphia chromosome–positive (Ph+) leukemia: phase 1/2 study update. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(15_suppl):7062. doi: 10.1200/JCO.2018.36.15_suppl.7062
   Web of Science ®Google Scholar
• Yüzbaşıoğlu MB, Eşkazan AE. Bosutinib – related pleural effusion in patients with chronic myeloid leukemia. Expert Opin Drug Saf. 2021 Apr;20(4):379–381. doi: 10.1080/14740338.2021.1867103 Epub 2021 Jan 8. PMID: 33339467.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jean Khoury H, Kantarjian H, et al. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016 Jun;91(6):606–16. doi: 10.1002/ajh.24360 Epub 2016 Apr 13. PMID: 26971533; PMCID PMC5548463.
   PubMed Web of Science ®Google Scholar
• Kwak JY, Kim SH, Oh SJ, et al. Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clin Cancer Res. 2017 Dec 1;23(23):7180–7188. doi: 10.1158/1078-0432.CCR-17-0957 Epub 2017 Sep 22. PMID: 28939746.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Keskin D. Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. Ther Adv Hematol. 2017 Sep;8(9):237–243. doi: 10.1177/2040620717719851
   PubMed Web of Science ®Google Scholar
• Kim SH, Menon H, Jootar S, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014 Jul;99(7):1191–6. doi: 10.3324/haematol.2013.096776 Epub 2014 Apr 4. PMID: 24705186; PMCID: PMC4077080.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Soysal T. Radotinib in the treatment of chronic phase chronic myeloid leukemia patients. Haematologica. 2015 Jan;100(1):e39. doi: 10.3324/haematol.2014.117846
   PubMed Web of Science ®Google Scholar
• Do YR, Kwak JY, Kim JA, et al. Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). Br J Haematol. 2020 Apr;189(2):303–312. doi: 10.1111/bjh.16381 Epub 2020 Feb 3. PMID: 32012231; PMCID: PMC7187446.
   PubMed Web of Science ®Google Scholar
• Gugliotta G, Castagnetti F, Fogli M, et al. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. Expert Rev Hematol. 2013 Oct;6(5):563–74. doi: 10.1586/17474086.2013.837279 Epub 2013 Oct 2. PMID: 24083631.
   PubMed Web of Science ®Google Scholar
• Erçalışkan A, Seyhan Erdoğan D, Eşkazan AE. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Adv. 2021 Sep 14;5(17):3344–3353. doi: 10.1182/bloodadvances.2021004194 PMID: 34477815; PMCID: PMC8525239.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Elverdi T, Yalniz FF, et al. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leuk Lymphoma. 2014 Dec;55(12):2935–7. doi: 10.3109/10428194.2014.905774 Epub 2014 May 6. PMID: 24650055.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Sadri S, Keskin D, et al. Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 Months: a comparative analysis of generic imatinib and glivec. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):804–811. doi: 10.1016/j.clml.2017.07.255 Epub 2017 Aug 4. PMID: 28847475.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Ayer M, Kantarcioglu B, et al. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. Br J Haematol. 2014 Oct;167(1):139–41. doi: 10.1111/bjh.12937 Epub 2014 May 10. PMID: 24815307.
   PubMed Web of Science ®Google Scholar
• Fava C, Rege-Cambrin G, Dogliotti I, et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019 Aug;104(8):1589–1596. doi: 10.3324/haematol.2018.205054 Epub 2019 Feb 28. PMID: 30819917; PMCID: PMC6669161.
   PubMed Web of Science ®Google Scholar
• Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10;123(15):2317–24. doi: 10.1182/blood-2013-10-532341 Epub 2014 Feb 25. PMID: 24569263; PMCID: PMC4915794.
   PubMed Web of Science ®Google Scholar
• Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan;27(1):107–12.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica. 2018 Aug;103(8):1298–1307. doi: 10.3324/haematol.2017.171249 Epub 2018 May 17. PMID: 29773593; PMCID: PMC6068045.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15;109(6):2303–2309. doi: 10.1182/blood-2006-09-047266 Epub 2006 Nov 30. Erratum in: Blood. 2007 Sep 1;110(5):1438. PMID: 17138817.
   PubMed Web of Science ®Google Scholar
• Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 Sep;91(9):869–74. doi: 10.1002/ajh.24423 Epub 2016 Jun 20. PMID: 27192969; PMCID: PMC5094534.
   PubMed Web of Science ®Google Scholar
• Markovic U, Bulla A, Leotta S, et al. Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients. Anticancer Res. 2020 Sep;40(9):5313–5317. doi: 10.21873/anticanres.14538 PMID: 32878823.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer. 2011 Mar 1;117(5):897–906. doi: 10.1002/cncr.25656 Epub 2010 Oct 13. PMID: 20945321; PMCID: PMC4428165.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27;117(4):1141–5. doi: 10.1182/blood-2010-03-277152 Epub 2010 Nov 22. PMID: 21098399; PMCID: PMC4916554.
   PubMed Web of Science ®Google Scholar
• Hiwase D, Tan P, D’Rozario J, et al. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the phase IIIb ENESTswift study. Leuk Res. 2018 Apr;67:109–115. doi: 10.1016/j.leukres.2018.02.013 Epub 2018 Feb 21. PMID: 29494928.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. PACE investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 7;369(19):1783–1796. doi: 10.1056/NEJMoa1306494 Epub 2013 Nov 1. PMID: 24180494; PMCID: PMC3886799.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4);393–404. doi: 10.1182/blood-2016-09-739086 Epub 2018 Mar 22. PMID: 29567798; PMCID: PMC6071555.
   PubMed Web of Science ®Google Scholar
• Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021 Nov 25;138(21);2042–2050. doi: 10.1182/blood.2021012082 PMID: 34407543; PMCID: PMC9728404.
   PubMed Web of Science ®Google Scholar
• Iurlo A, Cattaneo D, Orofino N, et al. Low-dose ponatinib in intolerant chronic myeloid leukemia patients: A safe and effective option. Clin Drug Investig. 2018 May;38(5):475–476. doi: 10.1007/s40261-018-0623-7 PMID: 29363026.
   PubMed Web of Science ®Google Scholar
• Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020 Nov;98:106458. doi: 10.1016/j.leukres.2020.106458 Epub 2020 Sep 29. PMID: 33096322.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019 Dec 12;381(24):2315–2326. doi: 10.1056/NEJMoa1902328 PMID: 31826340; PMCID: PMC7724923.
   PubMed Web of Science ®Google Scholar
• İbiş B, Tiribelli M, Eşkazan AE. Asciminib as a new option in the treatment of chronic myeloid leukemia. Future Oncol. 2021 Dec;17(36):5003–5005. doi: 10.2217/fon-2021-1174 Epub 2021 Nov 18. PMID: 34791894.
   PubMed Web of Science ®Google Scholar
• Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 Nov 25;138(21):2031–2041. doi: 10.1182/blood.2020009984 PMID: 34407542; PMCID: PMC9728405.
   PubMed Web of Science ®Google Scholar
• Luna A, Pérez-Lamas L, Boque C, et al. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Ann Hematol. 2022 Oct;101(10):2263–2270. doi: 10.1007/s00277-022-04932-6 Epub 2022 Aug 23. PMID: 35997804; PMCID: PMC9463214.
   PubMed Web of Science ®Google Scholar
• Shanmuganathan N, Hughes TP. Asciminib for chronic myeloid leukaemia: Next questions. Br J Haematol. 2022 Nov;199(3):322–331. doi: 10.1111/bjh.18323 Epub 2022 Jun 21. PMID: 35729850.
   PubMed Web of Science ®Google Scholar
• Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, et al. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8 PMID: 33563899; PMCID: PMC7873237.
   PubMed Web of Science ®Google Scholar
• Ren X, Pan X, Zhang Z, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-abelson (bcr-abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013 Feb 14;56(3):879–894. doi: 10.1021/jm301581y Epub 2013 Jan 28. PMID: 23301703.
   PubMed Web of Science ®Google Scholar
• Öziskender R, Eşkazan AE. Olverembatinib in chronic myeloid leukemia. Drugs Today (Barc). 2022 Nov;58(11):531–538. doi: 10.1358/dot.2022.58.11.3441854 PMID: 36422514.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022 Aug;15(1):113. doi: 10.1186/s13045-022-01334-z Erratum in: J Hematol Oncol. 2022 Oct 31;15(1):159. Erratum in: J Hematol Oncol. 2023 Feb 20;16(1):13. PMID: 35982483; PMCID: PMC9389804.
   PubMed Web of Science ®Google Scholar
• Etienne G, Dulucq S, Nicolini FE, et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica. 2014 Mar;99(3):458–64. doi: 10.3324/haematol.2013.095158 Epub 2013 Dec 20. PMID: 24362549; PMCID: PMC3943308.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Cortes JE, Zyczynski T, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019 Jan;94(1):46–54. doi: 10.1002/ajh.25306 Epub 2018 Oct 31. PMID: 30290003; PMCID: PMC6587733.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Chen C, Davis C, et al. Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data. Eur J Haematol. 2021 Jan;106(1):82–89. doi: 10.1111/ejh.13524 Epub 2020 Oct 9. PMID: 32989776; PMCID: PMC7756290.
   PubMed Web of Science ®Google Scholar
• Chow EJ, Doody DR, Wilkes JJ, et al. Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees. Leuk Lymphoma. 2021 May;62(5):1203–1210. doi: 10.1080/10428194.2020.1855340 Epub 2020 Dec 7. PMID: 33283555; PMCID: PMC8106632.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Goldberg SL, Mauro MJ, et al. Cross-Intolerance with dasatinib among imatinib-intolerant patients with chronic phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. Clin Lymphoma Myeloma Leukemia. 2016 Jun;16(6):341–349.e1. doi: 10.1016/j.clml.2016.03.004 Epub 2016 Mar 29. PMID: 27133948.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010 May 10;28(14):2381–8. doi: 10.1200/JCO.2009.26.3087 Epub 2010 Apr 12. PMID: 20385986; PMCID: PMC6366340.
   PubMed Web of Science ®Google Scholar
• Flynn KE, Atallah E. Quality of life and long-term therapy in patients with chronic myeloid leukemia. Curr Hematol Malig Rep. 2016 Apr;11(2):80–5. doi: 10.1007/s11899-016-0306-5 PMID: 26879546; PMCID: PMC4860261.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. GIMEMA. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011 Oct 27;118(17):4554–60. doi: 10.1182/blood-2011-04-347575 Epub 2011 Jul 12. PMID: 21750313.
   PubMed Web of Science ®Google Scholar
• Bidikian A, Jabbour E, Issa GC, et al. Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor. Am J Hematol. 2023 Apr;98(4):639–644. doi: 10.1002/ajh.26836 Epub 2023 Jan 16. PMID: 36606715.
   PubMed Web of Science ®Google Scholar
• Sanz A, Ayala R, Hernández G, et al. Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network. Blood Cancer J. 2022 Jun 24;12(6):94. doi: 10.1038/s41408-022-00692-8 PMID: 35750670; PMCID: PMC9232604.
   PubMed Web of Science ®Google Scholar